A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 232 participants.

Also called NCT03320031

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 232 participants (planned count) (from the registry)
Sponsor
Yanbing Li (from the registry)
Registry
  • NCT NCT03320031
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03320031. Randomized; no masking; primary purpose treatment. Start 2017-06-03 (actual); primary completion 2019-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy
Condition
Type 2 Diabetes Mellitus
Condition
Peritoneal Dialysis
Intervention (Drug)
Linagliptin
Intervention (Drug)
Humalog Mix 75/25
Lead sponsor
Yanbing Li (class: other)

Record details

Record id
cardio:ct-nct03320031
Content hash
2d2532a1fb02b3f52061467314a13331ee852102de93ed5a44f9fcf66fbea914